INR 100.95
(-1.17%)
Year | Operating Expenses | Operating Expenses Growth |
---|---|---|
2023 | 555.62 Million INR | -51.87% |
2022 | 1.15 Billion INR | 19.28% |
2021 | 967.88 Million INR | 17.72% |
2020 | 822.15 Million INR | -6.68% |
2019 | 881.02 Million INR | -5.25% |
2018 | 929.87 Million INR | -3.66% |
2017 | 965.2 Million INR | -7.28% |
2016 | 1.04 Billion INR | 26.46% |
2015 | 823.17 Million INR | 6.12% |
2014 | 775.69 Million INR | 10.02% |
2013 | 705.02 Million INR | 24.67% |
2012 | 565.52 Million INR | 8.32% |
2011 | 522.08 Million INR | 14.88% |
2010 | 454.48 Million INR | 4.19% |
2009 | 436.18 Million INR | 4.92% |
2008 | 415.73 Million INR | 16.66% |
2007 | 356.36 Million INR | 0.0% |
Year | Operating Expenses | Operating Expenses Growth |
---|---|---|
2024 Q1 | 139.08 Million INR | -11.03% |
2023 Q3 | 309.84 Million INR | -8.73% |
2023 Q4 | 156.31 Million INR | -49.55% |
2023 FY | 555.62 Million INR | -51.87% |
2023 Q1 | 266.56 Million INR | -14.77% |
2023 Q2 | 339.49 Million INR | 27.36% |
2022 Q4 | 312.75 Million INR | 11.56% |
2022 Q3 | 280.33 Million INR | -6.46% |
2022 Q2 | 299.69 Million INR | 14.5% |
2022 Q1 | 261.73 Million INR | 4.94% |
2022 FY | 1.15 Billion INR | 19.28% |
2021 FY | 967.88 Million INR | 17.72% |
2021 Q1 | 196.52 Million INR | -12.42% |
2021 Q3 | 250.59 Million INR | -7.66% |
2021 Q2 | 271.37 Million INR | 38.09% |
2021 Q4 | 249.4 Million INR | -0.47% |
2020 Q1 | 193.04 Million INR | -3.17% |
2020 Q2 | 183.24 Million INR | -5.08% |
2020 Q3 | 221.48 Million INR | 20.87% |
2020 Q4 | 224.38 Million INR | 1.31% |
2020 FY | 822.15 Million INR | -6.68% |
2019 Q2 | 235.61 Million INR | 1.24% |
2019 Q4 | 199.36 Million INR | -6.54% |
2019 Q1 | 232.71 Million INR | 2.97% |
2019 Q3 | 213.31 Million INR | -9.46% |
2019 FY | 881.02 Million INR | -5.25% |
2018 Q4 | 226.01 Million INR | 6.59% |
2018 FY | 929.87 Million INR | -3.66% |
2018 Q3 | 212.04 Million INR | -21.94% |
2018 Q2 | 271.62 Million INR | 28.1% |
2018 Q1 | 212.04 Million INR | -24.54% |
2017 Q3 | 237.12 Million INR | 0.0% |
2017 Q4 | 281.01 Million INR | 18.51% |
2017 FY | 965.2 Million INR | -7.28% |
2016 FY | 1.04 Billion INR | 26.46% |
2016 Q2 | 269.97 Million INR | 28.77% |
2016 Q1 | 209.65 Million INR | -13.48% |
2016 Q4 | 317.72 Million INR | 17.43% |
2016 Q3 | 270.56 Million INR | 0.22% |
2015 Q4 | 242.3 Million INR | 15.89% |
2015 Q1 | 186.05 Million INR | -19.71% |
2015 FY | 823.17 Million INR | 6.12% |
2015 Q2 | 206.64 Million INR | 11.07% |
2015 Q3 | 209.07 Million INR | 1.17% |
2014 Q3 | 178.62 Million INR | -5.3% |
2014 FY | 775.69 Million INR | 10.02% |
2014 Q4 | 231.71 Million INR | 29.73% |
2014 Q2 | 188.61 Million INR | 6.72% |
2014 Q1 | 176.74 Million INR | -6.08% |
2013 Q4 | 188.18 Million INR | 8.76% |
2013 FY | 705.02 Million INR | 24.67% |
2013 Q2 | 175.26 Million INR | 3.98% |
2013 Q1 | 168.55 Million INR | 8.98% |
2013 Q3 | 173.02 Million INR | -1.28% |
2012 Q2 | 136.82 Million INR | 2.32% |
2012 Q4 | 154.66 Million INR | 10.23% |
2012 FY | 565.52 Million INR | 8.32% |
2012 Q1 | 133.71 Million INR | -9.59% |
2012 Q3 | 140.31 Million INR | 2.55% |
2011 FY | 522.08 Million INR | 14.88% |
2011 Q4 | 147.91 Million INR | 14.06% |
2011 Q3 | 129.68 Million INR | -0.94% |
2011 Q2 | 130.91 Million INR | 0.0% |
2010 FY | 454.48 Million INR | 4.19% |
2009 FY | 436.18 Million INR | 4.92% |
2008 FY | 415.73 Million INR | 16.66% |
2007 FY | 356.36 Million INR | 0.0% |
Name | Operating Expenses | Operating Expenses Difference |
---|---|---|
Amrutanjan Health Care Limited | 2.09 Billion INR | 73.466% |
Biofil Chemicals and Pharmaceuticals Limited | 6.82 Million INR | -8047.009% |
Caplin Point Laboratories Limited | 2.17 Billion INR | 74.448% |
FDC Limited | 3.49 Billion INR | 84.124% |
Gufic Biosciences Limited | 1.18 Billion INR | 53.175% |
Hikal Limited | 4.46 Billion INR | 87.553% |
Ind-Swift Laboratories Limited | 2.12 Billion INR | 73.843% |
IOL Chemicals and Pharmaceuticals Limited | 2.2 Billion INR | 74.756% |
Kilitch Drugs (India) Limited | 412.42 Million INR | -34.721% |
Medico Remedies Limited | 59.67 Million INR | -831.087% |
Nectar Lifesciences Limited | 932.7 Million INR | 40.428% |
Par Drugs and Chemicals Limited | 58.28 Million INR | -853.242% |
RPG Life Sciences Limited | 1.63 Billion INR | 66.027% |
Sequent Scientific Limited | 2.9 Billion INR | 80.852% |
Shilpa Medicare Limited | 3.33 Billion INR | 83.335% |
Sigachi Industries Limited | 579.88 Million INR | 4.184% |
Themis Medicare Limited | 1.12 Billion INR | 50.646% |
Unichem Laboratories Limited | 6.72 Billion INR | 91.739% |
Venus Remedies Limited | 1.91 Billion INR | 71.005% |
Wanbury Limited | 978.96 Million INR | 43.244% |
ZIM Laboratories Limited | 1.01 Billion INR | 45.154% |
Lupin Limited | 125.09 Billion INR | 99.556% |
Innova Captab Limited | 931.03 Million INR | 40.321% |
Ind-Swift Limited | 946.56 Million INR | 41.301% |
Bajaj HealthCare Limited | 985.34 Million INR | 43.611% |
Aurobindo Pharma Limited | 55.65 Billion INR | 99.002% |
Solara Active Pharma Sciences Limited | 2.55 Billion INR | 78.246% |
AstraZeneca Pharma India Limited | 2.47 Billion INR | 77.537% |
Mangalam Drugs & Organics Limited | 162.22 Million INR | -242.497% |
Morepen Laboratories Limited | 1.98 Billion INR | 72.043% |
Laurus Labs Limited | 11.9 Billion INR | 95.335% |
Aarti Drugs Limited | 1.16 Billion INR | 52.408% |
Glenmark Life Sciences Limited | 11.64 Billion INR | 95.227% |
Alembic Limited | 872.45 Million INR | 36.315% |
Alembic Pharmaceuticals Limited | 15.86 Billion INR | 96.499% |
Glenmark Pharmaceuticals Limited | 46.95 Billion INR | 98.817% |
Vaishali Pharma Limited | 84.02 Million INR | -561.231% |
Aarti Pharmalabs Limited | 3.07 Billion INR | 81.927% |
Jagsonpal Pharmaceuticals Limited | 438.55 Million INR | -26.696% |
Jubilant Pharmova Limited | 14.45 Billion INR | 96.156% |
Eris Lifesciences Limited | 4.94 Billion INR | 88.759% |
Windlas Biotech Limited | 1 Billion INR | 44.797% |
Sun Pharmaceutical Industries Limited | 154.18 Billion INR | 99.64% |
Lincoln Pharmaceuticals Limited | 1.07 Billion INR | 48.275% |
Orchid Pharma Limited | 800.77 Million INR | 30.614% |
Albert David Limited | 1.02 Billion INR | 45.853% |
Hester Biosciences Limited | 908.84 Million INR | 38.864% |
Sakar Healthcare Limited | 204.07 Million INR | -172.26% |
Suven Pharmaceuticals Limited | 1.4 Billion INR | 60.391% |
Procter & Gamble Health Limited | 2.99 Billion INR | 81.451% |
Divi's Laboratories Limited | 14.17 Billion INR | 96.079% |
Mankind Pharma Limited | 29.27 Billion INR | 98.102% |
Neuland Laboratories Limited | 2.92 Billion INR | 81.035% |
J. B. Chemicals & Pharmaceuticals Limited | 14.79 Billion INR | 96.244% |
Zydus Lifesciences Limited | 125.21 Billion INR | 99.556% |
Wockhardt Limited | 8.48 Billion INR | 93.448% |
Dr. Reddy's Laboratories Limited | 95.87 Billion INR | 99.42% |
Bliss GVS Pharma Limited | 1.41 Billion INR | 60.85% |
Alkem Laboratories Limited | 32.83 Billion INR | 98.308% |
Valiant Laboratories Limited | 138.02 Million INR | -302.543% |
Ajanta Pharma Limited | 30.46 Billion INR | 98.176% |
Bafna Pharmaceuticals Limited | 455.58 Million INR | -21.959% |
Aarey Drugs & Pharmaceuticals Limited | 14.21 Million INR | -3809.28% |
Granules India Limited | 10.31 Billion INR | 94.612% |
Medicamen Biotech Limited | 335.16 Million INR | -65.776% |
Ipca Laboratories Limited | 18.98 Billion INR | 97.074% |
Brooks Laboratories Limited | 51.18 Million INR | -985.631% |
Syncom Formulations (India) Limited | 345.63 Million INR | -60.756% |
Piramal Enterprises Limited | 63.65 Billion INR | 99.127% |
Torrent Pharmaceuticals Limited | 21.42 Billion INR | 97.406% |
NATCO Pharma Limited | 10.05 Billion INR | 94.476% |
Suven Life Sciences Limited | 109.75 Million INR | -406.265% |
Krebs Biochemicals & Industries Limited | 46.15 Million INR | -1103.8% |
Strides Pharma Science Limited | 9.16 Billion INR | 93.936% |
Indoco Remedies Limited | 12.06 Billion INR | 95.393% |
Alpa Laboratories Limited | 127.38 Million INR | -336.196% |
Lasa Supergenerics Limited | 291.17 Million INR | -90.823% |
Sun Pharma Advanced Research Company Limited | 3.07 Billion INR | 81.941% |